Literature DB >> 23903558

¹²³I-FP-Cit and 123I-IBZM SPECT uptake in a prospective normal material analysed with two different semiquantitative image evaluation tools.

Susanna Jakobson Mo1, Anne Larsson, Jan Linder, Richard Birgander, Lars Edenbrandt, Hans Stenlund, Lars Forsgren, Katrine Riklund.   

Abstract

OBJECTIVE: The need for age-adjusted and/or sex-adjusted reference values in dopamine transporter (DAT) and dopamine D2 receptor (D2R) imaging with single-photon emission computed tomography (SPECT) in a longitudinal study of parkinsonian diseases was investigated. We used two different image evaluation tools with a cross-sectional and longitudinal statistical approach.
MATERIALS AND METHODS: Baseline DAT and/or D2R SPECT were performed in 51 healthy controls (HC), age-matched to patients in an ongoing prospective study on idiopathic parkinsonism. Twenty-four HC were re-examined after 3 years and 21 HC were examined again after 5 years. SPECT was performed with I-FP-Cit and I-IBZM on a two-headed hybrid gamma camera. Regions of interest and volumes of interest (VOIs) were used for image evaluation. A cross-sectional and longitudinal statistical analysis was carried out.
RESULTS: Fewer sex-based differences and less age dependency were seen in DAT SPECT uptake ratios compared with D2R SPECT uptake ratios and when comparing uptake ratios obtained with regions of interest against those with VOIs. In the cross-sectional analysis, a significant age-dependent decline was seen in women in both DAT and D2R uptakes with the VOI method but not in men with either evaluation method. In the longitudinal dataset, both a slight decline and increase over time were seen in DAT uptake; however, a general pattern of decrease was seen in both men and women in D2R uptake.
CONCLUSION: The choice of the image evaluation method can influence the pattern of sex-based and age-related differences. The results speak for the use of age-stratified reference values for women, in particular when using a VOI method.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23903558     DOI: 10.1097/MNM.0b013e328364aa2e

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  10 in total

1.  Establishing On-Site Reference Values for (123)I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions.

Authors:  Nicolas Nicastro; Valentina Garibotto; Antoine Poncet; Simon Badoud; Pierre R Burkhard
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

2.  Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism.

Authors:  Susanna Jakobson Mo; Jan Linder; Lars Forsgren; Katrine Riklund
Journal:  Mov Disord Clin Pract       Date:  2014-09-30

3.  Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT.

Authors:  Helen Schmitz-Steinkrüger; Catharina Lange; Ivayla Apostolova; Franziska L Mathies; Lars Frings; Susanne Klutmann; Sabine Hellwig; Philipp T Meyer; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-31       Impact factor: 9.236

4.  The relationship between the dopaminergic system and depressive symptoms in cervical dystonia.

Authors:  E Zoons; M A J Tijssen; Y E M Dreissen; J D Speelman; M Smit; J Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-17       Impact factor: 9.236

5.  Neurofilament Levels Are Reflecting the Loss of Presynaptic Dopamine Receptors in Movement Disorders.

Authors:  Elena Diekämper; Britta Brix; Winfried Stöcker; Stefan Vielhaber; Imke Galazky; Michael C Kreissl; Philipp Genseke; Emrah Düzel; Péter Körtvelyessy
Journal:  Front Neurosci       Date:  2021-12-03       Impact factor: 4.677

6.  Neurofilament light as a biomarker for motor decline in Parkinson's disease.

Authors:  Yumei Liu; Kaixin Dou; Ling Xue; Xiaoyuan Li; Anmu Xie
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

7.  Japanese multicenter database of healthy controls for [123I]FP-CIT SPECT.

Authors:  Hiroshi Matsuda; Miho Murata; Yohei Mukai; Kazuya Sako; Hidetoshi Ono; Hiroshi Toyama; Yoshitaka Inui; Yasuyuki Taki; Hideo Shimomura; Hiroshi Nagayama; Amane Tateno; Kenjiro Ono; Hidetomo Murakami; Atsushi Kono; Shigeki Hirano; Satoshi Kuwabara; Norihide Maikusa; Masayo Ogawa; Etsuko Imabayashi; Noriko Sato; Harumasa Takano; Jun Hatazawa; Ryosuke Takahashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-24       Impact factor: 9.236

8.  Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT-a clinical comparison.

Authors:  Susanna Jakobson Mo; Jan Axelsson; Lars Jonasson; Anne Larsson; Mattias J Ögren; Margareta Ögren; Andrea Varrone; Linda Eriksson; David Bäckström; Sara Af Bjerkén; Jan Linder; Katrine Riklund
Journal:  EJNMMI Res       Date:  2018-11-15       Impact factor: 3.138

9.  Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study.

Authors:  David Bäckström; Gabriel Granåsen; Magdalena Eriksson Domellöf; Jan Linder; Susanna Jakobson Mo; Katrine Riklund; Henrik Zetterberg; Kaj Blennow; Lars Forsgren
Journal:  Neurology       Date:  2018-10-31       Impact factor: 9.910

10.  NfL as a biomarker for neurodegeneration and survival in Parkinson disease.

Authors:  David Bäckström; Jan Linder; Susanna Jakobson Mo; Katrine Riklund; Henrik Zetterberg; Kaj Blennow; Lars Forsgren; Niklas Lenfeldt
Journal:  Neurology       Date:  2020-07-17       Impact factor: 11.800

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.